The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...

Dave Miller, PhD, explains how a development-first approach, scientific depth, and regulatory trust build lasting partnerships in the CDMO space.

The company is not developing an mRNA vaccine, but had been using one as the control in a 10,000-subject Phase IIb trial.

The new targeted pipeline will advance Nxera’s oral GLP-1 agonists, novel GPCR targets, and structure-based drug design to ...

Dave Miller, PhD, discusses how tailored solutions, trust, and lifecycle planning are redefining partnerships in bio/pharmaceutical development.

Thermoplastic elastomers (TPE) offer a PFAS-free solution for stoppers in parenteral packaging, ensuring a safer and more ...

The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

FDA reinstates Vinay Prasad to lead CBER as gene therapy safety concerns spotlight regulatory challenges in biotech manufacturing.

Experts from LGM Pharma and Rockwell Automation share their thoughts on what makes tech transfer effective, where processes ...

The agency’s new program is designed to increase regulatory predictability and streamline review of domestic manufacturing ...

The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial ...

Radiopharmaceuticals are moving from their standard use of treating superficial tumors into radio drug conjugates that target ...